Sol Gel Technologies Ltd (SLGL) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sol Gel Technologies Ltd stock (SLGL) is currently trading at $80.01. Sol Gel Technologies Ltd PS ratio (Price-to-Sales) is 9.51. Analyst consensus price target for SLGL is $50.00. WallStSmart rates SLGL as Sell.
- SLGL PE ratio analysis and historical PE chart
- SLGL PS ratio (Price-to-Sales) history and trend
- SLGL intrinsic value — DCF, Graham Number, EPV models
- SLGL stock price prediction 2025 2026 2027 2028 2029 2030
- SLGL fair value vs current price
- SLGL insider transactions and insider buying
- Is SLGL undervalued or overvalued?
- Sol Gel Technologies Ltd financial analysis — revenue, earnings, cash flow
- SLGL Piotroski F-Score and Altman Z-Score
- SLGL analyst price target and Smart Rating
Sol Gel Technologies
📊 No data available
Try selecting a different time range
Smart Analysis
Sol Gel Technologies Ltd (SLGL) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, revenue growth, eps growth. Concerns around market cap and return on equity. Mixed signals suggest waiting for clearer direction before acting.
Sol Gel Technologies Ltd (SLGL) Key Strengths (3)
Keeps $65 of every $100 in revenue after operating costs
Revenue surging 217.70% year-over-year
Earnings per share surging 487.60% year-over-year
Supporting Valuation Data
Sol Gel Technologies Ltd (SLGL) Areas to Watch (6)
Company is destroying shareholder value
Company is losing money with a negative profit margin
Very expensive at 9.5x annual revenue
Very expensive at 7.8x book value
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Sol Gel Technologies Ltd (SLGL) Detailed Analysis Report
Overall Assessment
This company scores 40/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 3 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Revenue Growth, EPS Growth. Profitability is solid with Operating Margin at 65.10%. Growth metrics are encouraging with Revenue Growth at 217.70%, EPS Growth at 487.60%.
The Bear Case
The primary concerns are Return on Equity, Profit Margin, Price/Sales. Some valuation metrics including Price/Sales (9.51), Price/Book (7.81) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -10.20%, Profit Margin at -14.20%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -10.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 217.70% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Profit Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SLGL Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SLGL's Price-to-Sales ratio of 9.51x trades at a deep discount to its historical average of 36.25x (67th percentile). The current valuation is 96% below its historical high of 220.06x set in Jul 2019, and 7215% above its historical low of 0.13x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.1x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sol Gel Technologies Ltd (SLGL) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Sol Gel Technologies Ltd is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 24M with 218% growth year-over-year. The company is currently unprofitable, posting a -14.2% profit margin.
Key Findings
Revenue growing at 218% YoY, reaching 24M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Generating 275,000 in free cash flow and 322,000 in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -14.2% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can Sol Gel Technologies Ltd maintain 218%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Sol Gel Technologies Ltd.
Bottom Line
Sol Gel Technologies Ltd is a high-conviction growth story with revenue accelerating at 218% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -14.2% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sol Gel Technologies Ltd(SLGL)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.